{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:38:11Z","timestamp":1770813491940,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.7759\/cureus.103223","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:55:32Z","timestamp":1770598532000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Eghleilib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muaad","family":"Eghlileb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Eghlileb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.774808","article-title":"Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis","volume":"12","author":"Cai J","year":"2021","unstructured":"Cai J, Cui L, Wang Y, Li Y, Zhang X, Shi Y. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol. 2021, 12:774808. 10.3389\/fphar.2021.774808","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091101","article-title":"Looking beyond the skin: pathophysiology of cardiovascular comorbidity in psoriasis and the protective role of biologics","volume":"15","author":"And\u00fajar I","year":"2022","unstructured":"And\u00fajar I, Esplugues JV, Garc\u00eda-Mart\u00ednez P. Looking beyond the skin: pathophysiology of cardiovascular comorbidity in psoriasis and the protective role of biologics. Pharmaceuticals (Basel). 2022, 15:1101. 10.3390\/ph15091101","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.057","article-title":"Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study","volume":"191","author":"Bunick CG","year":"2024","unstructured":"Bunick CG, Grada A, Del Rosso J, Armstrong AW, Yue E, Krueger K. Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. Br J Dermatol. 2024, 191:10.1093\/bjd\/ljae266.057","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae324","article-title":"Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease","volume":"50","author":"Kearney N","year":"2025","unstructured":"Kearney N, Chen X, Bi Y, Hew K, Smith KM, Kirby B. Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease. Clin Exp Dermatol. 2025, 50:339-47. 10.1093\/ced\/llae324","journal-title":"Clin Exp Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105485","article-title":"Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis","volume":"111","author":"Kridin K","year":"2025","unstructured":"Kridin K, Bieber K, Vorobyev A, et al.. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine. 2025, 111:105485. 10.1016\/j.ebiom.2024.105485","journal-title":"EBioMedicine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004591","article-title":"Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study","volume":"22","author":"Lin TL","year":"2025","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med. 2025, 22:1004591. 10.1371\/journal.pmed.1004591","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0b013e31826579aa","article-title":"Biologic therapy","volume":"35","author":"Eisenberg S","year":"2012","unstructured":"Eisenberg S. Biologic therapy. J Infus Nurs. 2012, 35:301-13. 10.1097\/NAN.0b013e31826579aa","journal-title":"J Infus Nurs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072455","article-title":"Early detection and progression of subclinical atherosclerosis in psoriasis (Edsap): protocol for an observational, single-centre, prospective cohort study","volume":"13","author":"Abbad-Jaime de Arag\u00f3n C","year":"2023","unstructured":"Abbad-Jaime de Arag\u00f3n C, Berna-Rico E, Ballester-Martinez MA, et al.. Early detection and progression of subclinical atherosclerosis in psoriasis (Edsap): protocol for an observational, single-centre, prospective cohort study. BMJ Open. 2023, 13:072455. 10.1136\/bmjopen-2023-072455","journal-title":"BMJ Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.042","article-title":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate","volume":"76","author":"Wu JJ","year":"2017","unstructured":"Wu JJ, Gu\u00e9rin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate. J Am Acad Dermatol. 2017, 76:81-90. 10.1016\/j.jaad.2016.07.042","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon KB","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al.. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016, 375:345-56. 10.1056\/NEJMoa1512711","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017, 76:405-17. 10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan W","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZ, Warren RB, Griffiths CE, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017, 176:890-901. 10.1111\/bjd.14964","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.03.429","article-title":"Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa","volume":"143","author":"Gunter SJ","year":"2023","unstructured":"Gunter SJ, Porter ML, Gibson R, Kimball AB. Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa. J Invest Dermatol. 2023, 143:73. 10.1016\/j.jid.2023.03.429","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk K","year":"2011","unstructured":"Wolk K, Warszawska K, Hoeflich C, et al.. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011, 186:1228-39. 10.4049\/jimmunol.0903907","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03601-0","article-title":"The cardiometabolic safety of dupilumab in atopic dermatitis: a global large-scale cohort study","volume":"317","author":"Kridin K","year":"2025","unstructured":"Kridin K, Abdelghaffar M, Ludwig RJ. The cardiometabolic safety of dupilumab in atopic dermatitis: a global large-scale cohort study. Arch Dermatol Res. 2025, 317:296. 10.1007\/s00403-024-03601-0","journal-title":"Arch Dermatol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016, 375:422-34. 10.1056\/NEJMoa1504370","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima K","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020, 383:141-50. 10.1056\/NEJMoa1917006","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez H","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al.. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021, 385:2431-40. 10.1056\/NEJMoa2111563","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter A","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al.. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007, 56:31.e1-15. 10.1016\/j.jaad.2006.07.017","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb AB","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al.. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004, 51:534-42. 10.1016\/j.jaad.2004.02.021","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby P","year":"2012","unstructured":"Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012, 32:2045-51. 10.1161\/ATVBAHA.108.179705","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson GK","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352:1685-95. 10.1056\/NEJMra043430","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke WH","year":"2015","unstructured":"Boehncke WH, Schonn MP. Psoriasis. Lancet. 2015, 386:983-94. 10.1016\/S0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta NN","year":"2010","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010, 31:1000-6. 10.1093\/eurheartj\/ehp567","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.860209","article-title":"Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis","volume":"26","author":"Puig L","year":"2015","unstructured":"Puig L, Strohal R, Husni ME, et al.. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat. 2015, 26:7-15. 10.3109\/09546634.2013.860209","journal-title":"J Dermatolog Treat"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.10.371","article-title":"Cardiovascular biomarkers in patients with psoriasis vulgaris and the effect of adalimumab therapy","volume":"315","author":"Kraml P","year":"2020","unstructured":"Kraml P, Gkalpakiotis S, Arenbergerov\u00e1 M, et al.. Cardiovascular biomarkers in patients with psoriasis vulgaris and the effect of adalimumab therapy. Atherosclerosis. 2020, 315:121. 10.1016\/j.atherosclerosis.2020.10.371","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-021-00640-2","article-title":"Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease","volume":"36","author":"Ikonomidis I","year":"2022","unstructured":"Ikonomidis I, Pavlidis G, Lambadiari V, et al.. Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease. J Hum Hypertens. 2022, 36:1113-20. 10.1038\/s41371-021-00640-2","journal-title":"J Hum Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff O","year":"2011","unstructured":"Ahlehoff O, Gislason GH, Charlot M, et al.. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011, 270:147-57. 10.1111\/j.1365-2796.2010.02310.x","journal-title":"J Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87766-y","article-title":"The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study","volume":"11","author":"Hong JR","year":"2021","unstructured":"Hong JR, Jeong H, Kim H, et al.. The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. Sci Rep. 2021, 11:8588. 10.1038\/s41598-021-87766-y","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.050","article-title":"The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: An observational cohort study","volume":"79","author":"Wu JJ","year":"2018","unstructured":"Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gu\u00e9rin A, Singh R, Ganguli A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: An observational cohort study. J Am Acad Dermatol. 2018, 79:60-8. 10.1016\/j.jaad.2018.02.050","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang ZS","year":"2016","unstructured":"Yang ZS, Lin NN, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016, 51:240-7. 10.1007\/s12016-016-8560-9","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1358","article-title":"LB1085 biologics reduce adverse cardiovascular outcomes in statin-treated psoriasis patients: a global population study","volume":"145","author":"Johnsen NA","year":"2025","unstructured":"Johnsen NA, Ma EJ, Yan M, et al.. LB1085 biologics reduce adverse cardiovascular outcomes in statin-treated psoriasis patients: a global population study. J Invest Dermatol. 2025, 145:189. 10.1016\/j.jid.2025.06.1358","journal-title":"J Invest Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.06.112","article-title":"Anti-tumor necrosis factor \u03b1 treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis","volume":"151","author":"Avgerinou G","year":"2011","unstructured":"Avgerinou G, Tousoulis D, Siasos G, et al.. Anti-tumor necrosis factor \u03b1 treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol. 2011, 151:382-3. 10.1016\/j.ijcard.2011.06.112","journal-title":"Int J Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13398","article-title":"Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study","volume":"43","author":"Pina T","year":"2016","unstructured":"Pina T, Corrales A, Lopez-Mejias R, et al.. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol. 2016, 43:1267-72. 10.1111\/1346-8138.13398","journal-title":"J Dermatol"},{"key":"ref35","article-title":"Reduction in C-reactive protein levels with adalimumab therapy in patients with moderate to severe hand and\/or foot psoriasis","volume":"74","author":"Leonardi CL","year":"2016","unstructured":"Leonardi CL, Unnebrink K, Valdecantos WC. Reduction in C-reactive protein levels with adalimumab therapy in patients with moderate to severe hand and\/or foot psoriasis. J Drugs Dermatol. 2016, 74:266.","journal-title":"J Drugs Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00872.x","article-title":"Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies","volume":"25","author":"Angel K","year":"2011","unstructured":"Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol. 2011, 25:511-7. 10.1111\/j.1472-8206.2010.00872.x","journal-title":"Fundam Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12372","article-title":"Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy","volume":"28","author":"Strober BE","year":"2014","unstructured":"Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol. 2014, 28:1701-6. 10.1111\/jdv.12372","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14110","article-title":"Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study","volume":"33","author":"Gkalpakiotis S","year":"2020","unstructured":"Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study. Dermatol Ther. 2020, 33:14110. 10.1111\/dth.14110","journal-title":"Dermatol Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/039463200702000408","article-title":"Effect of etanercept on insulin sensitivity in nine patients with psoriasis","volume":"20","author":"Marra M","year":"2007","unstructured":"Marra M, Campanati A, Testa R, et al.. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007, 20:731-6. 10.1177\/039463200702000408","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-007-0784-3","article-title":"Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus","volume":"299","author":"Mart\u00ednez-Abundis E","year":"2007","unstructured":"Mart\u00ednez-Abundis E, Reynoso-von Drateln C, Hern\u00e1ndez-Salazar E, Gonz\u00e1lez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007, 299:461-5. 10.1007\/s00403-007-0784-3","journal-title":"Arch Dermatol Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2008.02.006","article-title":"Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis","volume":"57","author":"Saraceno R","year":"2008","unstructured":"Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008, 57:290-5. 10.1016\/j.phrs.2008.02.006","journal-title":"Pharmacol Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.2286","article-title":"Psoriasis severity and the risk of left ventricular remodelling in psoriasis patients treated with infliximab","volume":"42","author":"Linde A","year":"2021","unstructured":"Linde A, Midtbo H, Gerdts E, Kringeland E, Tveit KS. Psoriasis severity and the risk of left ventricular remodelling in psoriasis patients treated with infliximab. Eur Heart J. 2021, 42:10.1093\/eurheartj\/ehab724.2286","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan A","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009, 60:539-61. 10.1016\/j.jaad.2008.11.911","journal-title":"J Am Acad Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis","volume":"71","author":"Shlyankevich J","year":"2014","unstructured":"Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014, 71:1144-50. 10.1016\/j.jaad.2014.09.012","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa","volume":"103","author":"Jim\u00e9nez-Gallo D","year":"2018","unstructured":"Jim\u00e9nez-Gallo D, de la Varga-Mart\u00ednez R, Ossorio-Garc\u00eda L, Collantes-Rodr\u00edguez C, Rodr\u00edguez C, Linares-Barrios M. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine. 2018, 103:20-4. 10.1016\/j.cyto.2017.12.020","journal-title":"Cytokine"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine immune therapy and atherothrombotic cardiovascular risk","volume":"39","author":"Ait-Oufella H","year":"2019","unstructured":"Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler Thromb Vasc Biol. 2019, 39:1510-9. 10.1161\/ATVBAHA.119.311998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung ES","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003, 107:3133-40. 10.1161\/01.CIR.0000077913.60364.D2","journal-title":"Circulation"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1740204","article-title":"Safety update of etanercept treatment for moderate to severe plaque psoriasis","volume":"19","author":"Campanati A","year":"2020","unstructured":"Campanati A, Diotallevi F, Martina E, Paolinelli M, Radi G, Offidani A. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf. 2020, 19:439-48. 10.1080\/14740338.2020.1740204","journal-title":"Expert Opin Drug Saf"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp KA","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al.. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008, 371:1675-84. 10.1016\/S0140-6736(08)60726-6","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi CL","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al.. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008, 371:1665-74. 10.1016\/S0140-6736(08)60725-4","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/hc3901.096721","article-title":"Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability","volume":"104","author":"Mallat Z","year":"2001","unstructured":"Mallat Z, Corbaz A, Scoazec A, Besnard S, Les\u00e8che G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001, 104:1598-603. 10.1161\/hc3901.096721","journal-title":"Circulation"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui A","year":"2006","unstructured":"Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86:515-81. 10.1152\/physrev.00024.2005","journal-title":"Physiol Rev"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich K","year":"2011","unstructured":"Reich K, Langley RG, Lebwohl M, et al.. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011, 164:862-72. 10.1111\/j.1365-2133.2011.10257.x","journal-title":"Br J Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2321194","article-title":"Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-\u03b1 and interleukin-12\/23 inhibitors: a nationwide population-based cohort study in Korea","volume":"35","author":"Cho H","year":"2024","unstructured":"Cho H, Kim YJ, Moon IJ, et al.. Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-\u03b1 and interleukin-12\/23 inhibitors: a nationwide population-based cohort study in Korea. J Dermatolog Treat. 2024, 35:2321194. 10.1080\/09546634.2024.2321194","journal-title":"J Dermatolog Treat"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.016","article-title":"Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers","volume":"93","author":"Banefelt J","year":"2025","unstructured":"Banefelt J, Skr\u00f6der H, Azzabi A, Sheahan A, Suruki R, Geldhof A. Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers. J Am Acad Dermatol. 2025, 93:104-14. 10.1016\/j.jaad.2025.03.016","journal-title":"J Am Acad Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13855","article-title":"Comparison of the risk of heart failure in psoriasis patients using anti-TNF \u03b1 inhibitors and ustekinumab","volume":"9","author":"Han JH","year":"2022","unstructured":"Han JH, Park HE, Kim YH, Jung JH, Lee JH, Park YM, Bang CH. Comparison of the risk of heart failure in psoriasis patients using anti-TNF \u03b1 inhibitors and ustekinumab. ESC Heart Fail. 2022, 9:1502-4. 10.1002\/ehf2.13855","journal-title":"ESC Heart Fail"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14582","article-title":"Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris","volume":"31","author":"Koschitzky M","year":"2022","unstructured":"Koschitzky M, Navrazhina K, Garshick MS, Gonzalez J, Han J, Garcet S, Krueger JG. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Exp Dermatol. 2022, 31:1341-51. 10.1111\/exd.14582","journal-title":"Exp Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis I","year":"2017","unstructured":"Ikonomidis I, Papadavid E, Makavos G, et al.. Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis. Circ Cardiovasc Imaging. 2017, 10:1665-74. 10.1161\/CIRCIMAGING.117.006283","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"140","author":"Gelfand JM","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, et al.. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol. 2020, 140:85-93.e2. 10.1016\/j.jid.2019.07.679","journal-title":"J Invest Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014, 371:326-38. 10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths CE","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al.. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015, 386:541-51. 10.1016\/S0140-6736(15)60125-8","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel C","year":"2009","unstructured":"Erbel C, Chen L, Bea F, et al.. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009, 183:8167-75. 10.4049\/jimmunol.0901126","journal-title":"J Immunol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon T","year":"2013","unstructured":"Simon T, Taleb S, Danchin N, et al.. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013, 34:570-7. 10.1093\/eurheartj\/ehs263","journal-title":"Eur Heart J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12124010","article-title":"Interleukin-17A-correlated myocarditis in patients with psoriasis: cardiac recovery following secukinumab administration","volume":"12","author":"Frustaci A","year":"2023","unstructured":"Frustaci A, Galea N, Dominici L, Verardo R, Alfarano M, Scialla R, Richetta AG. Interleukin-17A-correlated myocarditis in patients with psoriasis: cardiac recovery following secukinumab administration. J Clin Med. 2023, 12:4010. 10.3390\/jcm12124010","journal-title":"J Clin Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg A","year":"2018","unstructured":"Egeberg A, Wu JJ, Korman N, Solomon JA, Goldblum O, Zhao F, Mallbris L. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018, 79:104-109.e8. 10.1016\/j.jaad.2018.02.074","journal-title":"J Am Acad Dermatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.361","article-title":"33156 Molecular linkage between psoriasis vulgaris and inflammation in adipose tissue: modulation by secukinumab treatment in the ObePso study","volume":"87","author":"Garcet S","year":"2022","unstructured":"Garcet S, Blauvelt A, Muscianisi E. 33156 Molecular linkage between psoriasis vulgaris and inflammation in adipose tissue: modulation by secukinumab treatment in the ObePso study. J Am Acad Dermatol. 2022, 87:82. 10.1016\/j.jaad.2022.06.361","journal-title":"J Am Acad Dermatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes IB","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al.. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015, 386:1137-46. 10.1016\/S0140-6736(15)61134-5","journal-title":"Lancet"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease PJ","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al.. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017, 76:79-87. 10.1136\/annrheumdis-2016-209709","journal-title":"Ann Rheum Dis"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-s)","volume":"140","author":"Gelfand JM","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, et al.. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-s). J Invest Dermatol. 2020, 140:1784-1793.e2. 10.1016\/j.jid.2020.01.025","journal-title":"J Invest Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications","volume":"10","author":"von Stebut E","year":"2019","unstructured":"von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, Sch\u00e4ffler A. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019, 10:3096. 10.3389\/fimmu.2019.03096","journal-title":"Front Immunol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich K","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al.. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017, 390:276-88. 10.1016\/S0140-6736(17)31279-5","journal-title":"Lancet"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2512159","article-title":"Tildrakizumab 200\u2009mg: a step forward in psoriasis treatment with added metabolic benefits","volume":"36","author":"Lanna C","year":"2025","unstructured":"Lanna C, Rivieccio A, Cattani C, Artosi F, Bianchi L, Campione E. Tildrakizumab 200\u2009mg: a step forward in psoriasis treatment with added metabolic benefits. J Dermatolog Treat. 2025, 36:2512159. 10.1080\/09546634.2025.2512159","journal-title":"J Dermatolog Treat"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.3268","article-title":"Pos1524 durable clinically-meaningful improvements in health-related quality of life, fatigue, pain, and work productivity among patients with active psoriatic arthritis treated with risankizumab at week 100","volume":"82","author":"Kristensen LE","year":"2023","unstructured":"Kristensen LE, Soliman AM, Padilla B, Papp K, Ostor A. Pos1524 durable clinically-meaningful improvements in health-related quality of life, fatigue, pain, and work productivity among patients with active psoriatic arthritis treated with risankizumab at week 100. Ann Rheum Dis. 2023, 82:1123. 10.1136\/annrheumdis-2023-eular.3268","journal-title":"Ann Rheum Dis"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study","volume":"32","author":"Gordon KB","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, et al.. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018, 32:1940-9. 10.1111\/jdv.15012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15581","article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"89","author":"Woods RH","year":"2023","unstructured":"Woods RH. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). Br J Clin Pharmacol. 2023, 89:2386-95. 10.1111\/bcp.15581","journal-title":"Br J Clin Pharmacol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5337","article-title":"The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (resurface 1 and resurface 2)","volume":"19","author":"Menter MA","year":"2020","unstructured":"Menter MA, Mehta NN, Lebwohl MG, Gottlieb AB, Mendelsohn AM, Rozzo SJ, Leonardi C. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (resurface 1 and resurface 2). J Drugs Dermatol. 2020, 19:703-8. 10.36849\/JDD.2020.5337","journal-title":"J Drugs Dermatol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson EL","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al.. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016, 375:2335-48. 10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1582403","article-title":"A review of dupilumab in the treatment of atopic diseases","volume":"15","author":"Thibodeaux Q","year":"2019","unstructured":"Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019, 15:2129-39. 10.1080\/21645515.2019.1582403","journal-title":"Hum Vaccin Immunother"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01298-9","article-title":"Dupilumab: a review in chronic rhinosinusitis with nasal polyps","volume":"80","author":"Hoy SM","year":"2020","unstructured":"Hoy SM. Dupilumab: a review in chronic rhinosinusitis with nasal polyps. Drugs. 2020, 80:711-7. 10.1007\/s40265-020-01298-9","journal-title":"Drugs"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.01.015","article-title":"Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis","volume":"138","author":"Andersen YM","year":"2016","unstructured":"Andersen YM, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016, 138:310-312.e3. 10.1016\/j.jaci.2016.01.015","journal-title":"J Allergy Clin Immunol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.030","article-title":"Atopic eczema and major cardiovascular outcomes: a\u00a0systematic review and meta-analysis of population-based studies","volume":"143","author":"Ascott A","year":"2019","unstructured":"Ascott A, Mulick A, Yu AM, et al.. Atopic eczema and major cardiovascular outcomes: a\u00a0systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol. 2019, 143:1821-9. 10.1016\/j.jaci.2018.11.030","journal-title":"J Allergy Clin Immunol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5320","article-title":"Therapeutic effect of dupilumab on systemic and vascular inflammation in adults with severe atopic dermatitis: feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography","volume":"103","author":"Lee GW","year":"2023","unstructured":"Lee GW, Kim K, Kim SJ, et al.. Therapeutic effect of dupilumab on systemic and vascular inflammation in adults with severe atopic dermatitis: feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography. Acta Derm Venereol. 2023, 103:5320. 10.2340\/actadv.v103.5320","journal-title":"Acta Derm Venereol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.03.020","article-title":"Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin","volume":"11","author":"Leung DY","year":"2023","unstructured":"Leung DY, Bissonnette R, Kreimer S, et al.. Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin. J Allergy Clin Immunol Pract. 2023, 11:1421-8. 10.1016\/j.jaip.2023.03.020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong AW","year":"2022","unstructured":"Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022, 12:167-84. 10.1007\/s13555-021-00647-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1159\/000545148","article-title":"Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, and monocyte\/lymphocyte ratio: a post hoc analysis of three randomised clinical trials","volume":"241","author":"Kearney N","year":"2025","unstructured":"Kearney N, Gorecki P, Acciarri L, Buyze J, Akawung A, Merola JF, Kirby B. Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, and monocyte\/lymphocyte ratio: a post hoc analysis of three randomised clinical trials. Dermatology. 2025, 241:272-86. 10.1159\/000545148","journal-title":"Dermatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448069-cardiovascular-outcomes-associated-with-biologic-therapy-in-inflammatory-dermatologic-diseases-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:55:34Z","timestamp":1770598534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448069-cardiovascular-outcomes-associated-with-biologic-therapy-in-inflammatory-dermatologic-diseases-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.103223","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}